NLRP3炎性小体在慢性心力衰竭中的作用与机制

王敢; 钟江华

doi:10.13201/j.issn.1001-1439.2023.08.005

NLRP3炎性小体在慢性心力衰竭中的作用与机制

王敢¹,
钟江华^1, ,

- 中南大学湘雅医学院附属海口医院心血管内科(海口，570208)
基金项目:
海南省重点研发项目(No: ZDYF2019134); 海南省自然基金资助项目(No: 2018CXTD349)

详细信息

通讯作者: 钟江华, E-mail: zhong3882@163.com

中图分类号: R541.6

收稿日期: 2022-08-29

刊出日期: 2023-08-13

The role and mechanism of NLRP3 inflammasome in chronic heart failure

WANG Gan¹,
ZHONG Jianghua^1, ,

- Department of Cardiology, Haikou Hospital, Xiangya Medical College, Central South University, Haikou, 570208, China

More Information

Corresponding author: ZHONG Jianghua, E-mail: zhong3882@163.com

Received Date: 29 August 2022

Publish Date: 13 August 2023

摘要

摘要: 慢性心力衰竭(chronic heart failure，CHF)是各类心血管疾病的终末期阶段。CHF的治疗方案近年虽不断完善，但仍有较高的死亡率与住院率，给患者及家庭带来了巨大的医疗负担。CHF的具体机制目前尚未完全明确，寻找CHF发生发展的病理生理机制及相关治疗靶点迫在眉睫。已知炎症在CHF的发展中起着重要作用，而NLRP3炎性小体可能在其中起重要的桥梁与驱动作用。但在CHF的发展过程中，不同病理条件下的NLRP3炎性小体激活机制有所差异。并且激活后的NLRP3炎性小体对不同的细胞可产生不同的病理作用。了解NLRP3炎性小体的激活机制及其在CHF中的作用或许可为CHF提供新的治疗靶点。本文就NLRP3炎性小体在CHF发生发展中的作用、机制及相关治疗作一综述。
- 炎症 /
- NLRP3 /
- 炎性小体 /
- 慢性心力衰竭 /
- 机制
Abstract: Chronic heart failure(CHF) is the terminal stage of cardiovascular disease. Although the treatment of CHF has been continuously improved in recent years, there are still high mortality and hospitalization rates, which bring huge medical burden to patients and families. The specific mechanism of CHF has not yet been fully clarified. It is urgent to find the pathophysiological mechanism and related therapeutic targets of CHF. It is known that inflammation plays an important role in the development of CHF, and NLRP3 inflammasome may play an important bridge and driving role. However, in the development of CHF, the mechanism of NLRP3 inflammasome activation is different under different pathological conditions. And the activated NLRP3 inflammasome can have different pathological effects on different cells. and targeted therapy for NLRP3 inflammasome has also made progress in recent years. In this paper, we review the role, mechanism and related treatment of NLRP3 inflammasome in the development of CHF.
- inflammation /
- NLRP3 /
- inflammasome /
- chronic heart failure /
- mechanism

HTML全文

图 1 不同病理模型下NLRP3炎性小体的激活方式

Figure 1. Activation of NLRP3 inflammasome in different pathological models

下载: 全尺寸图片幻灯片

图 2 NLRP3炎性小体对不同细胞产生不同影响

Figure 2. NLRP3 inflammasome has different effects on different cells

下载: 全尺寸图片幻灯片

参考文献(47)

[1]	Savarese G, Lund LH. Global public health burden of heart failure[J]. Card Fail Rev, 2017, 3(1): 7-11. doi: 10.15420/cfr.2016:25:2
[2]	Groenewegen A, Rutten FH, Mosterd A, et al. Epidemiology of heart failure[J]. Euro J Heart Fail, 2020, 22(8): 1342-1356. doi: 10.1002/ejhf.1858
[3]	Castillo EC, Vázquez-Garza E, Yee-Trejo D, et al. What is the role of the inflammation in the pathogenesis of heart failure?[J]. Curr Cardiol Rep, 2020, 22(11): 139. doi: 10.1007/s11886-020-01382-2
[4]	Murphy SP, Kakkar R, McCarthy CP, et al. Inflammation in heart failure: JACC State-of-the-Art Review[J]. J Am Coll Cardiol, 2020, 75(11): 1324-1340.
[5]	Zhong J, Shi G. Regulation of inflammation in chronic disease[J]. Frontiers in Immunology, 2019, 10: 737. doi: 10.3389/fimmu.2019.00737
[6]	李建军, 杨进刚. "融合"学说: 胆固醇, 炎症与动脉粥样硬化的新视野[J]. 临床心血管病杂志, 2022, 38(4): 265-266. https://lcxxg.whuhzzs.com/article/doi/10.13201/j.issn.1001-1439.2022.04.002
[7]	Mesquita T, Lin YN, Ibrahim A. Chronic low-grade inflammation in heart failure withpreserved ejection fraction[J]. Aging Cell, 2021, 20(9): e13453.
[8]	Huang Y, Xu W, Zhou R. NLRP3 inflammasome activation and cell death[J]. Cell Mol Immunol, 2021, 18(9): 2114-2127. doi: 10.1038/s41423-021-00740-6
[9]	Paik S, Kim JK, Silwal P, et al. An update on the regulatory mechanisms of NLRP3 inflammasome activation[J]. Cell Mol Immunol, 2021, 18(5): 1141-1160. doi: 10.1038/s41423-021-00670-3
[10]	Suetomi T, Willeford A, Brand CS, et al. Inflammation and NLRP3 inflammasome activation initiated in response to pressure overload by Ca2+/Calmodulin-dependent protein kinase Ⅱ δ signaling in cardiomyocytes are essential for adverse cardiac remodeling[J]. Circulation, 2018, 138(22): 2530-2544. doi: 10.1161/CIRCULATIONAHA.118.034621
[11]	Willeford A, Suetomi T, Nickle A, et al. CaMKIIδ-mediated inflammatory gene expression and inflammasome activation in cardiomyocytes initiate inflammation and induce fibrosis[J]. JCI Insight, 2018, 3(12): 111.
[12]	Marchetti C, Toldo S, Chojnacki J, et al. Pharmacologic Inhibition of the NLRP3 Inflammasome Preserves Cardiac Function After Ischemic and Nonischemic Injury in the Mouse[J]. J Cardiovasc Pharmacol, 2015, 66(1): 1-8. doi: 10.1097/FJC.0000000000000247
[13]	Segiet OA, Piecuch A, Mielanczyk L, et al. Role of interleukins in heart failure with reduced ejection fraction[J]. Anatol J Cardiol, 2019, 22(6): 287-299.
[14]	Baum JR, Long B, Cabo C, et al. Myofibroblasts cause heterogeneous Cx43 reduction and are unlikely to be coupled to myocytes in the healing canine infarct[J]. Am J Physiol Heart Circ Physiol, 2012, 302(3): H790-800. doi: 10.1152/ajpheart.00498.2011
[15]	Bracey NA, Beck PL, Muruve DA, et al. The Nlrp3 inflammasome promotes myocardial dysfunction in structural cardiomyopathy through interleukin-1β[J]. Exp Physiol, 2013, 98(2): 462-472. doi: 10.1113/expphysiol.2012.068338
[16]	Xiao H, Li H, Wang JJ, et al. IL-18 cleavage triggers cardiac inflammation and fibrosis upon β-adrenergic insult[J]. Eur Heart J, 2018, 39(1): 60-69. doi: 10.1093/eurheartj/ehx261
[17]	黄兰松, 刘燕, 黄照河. 细胞焦亡及其在心肌缺血再灌注损伤中作用机制[J]. 临床心血管病杂志, 2021, 35(2): 111-116. https://lcxxg.whuhzzs.com/article/doi/10.13201/j.issn.1001-1439.2021.02.019
[18]	Wang Q, Wu J, Zeng Y, et al. Pyroptosis: A pro-inflammatory type of cell death in cardiovascular disease[J]. Clin Chim Acta, 2020, 510: 62-72. doi: 10.1016/j.cca.2020.06.044
[19]	Shen S, Wang Z, Sun H, et al. Role of NLRP3 Inflammasome in Myocardial Ischemia-Reperfusion Injury and Ventricular Remodeling[J]. Med Sci Monit, 2022, 28: e934255.
[20]	Sharif H, Wang L, Wang WL, et al. Structural mechanism for NEK7-licensed activation of NLRP3 inflammasome[J]. Nature, 2019, 570(7761): 338-343. doi: 10.1038/s41586-019-1295-z
[21]	Xu Z, Chen ZM, Wu X, et al. Distinct molecular mechanisms underlying potassium efflux for NLRP3 inflammasome activation[J]. Front Immunol, 2020, 11: 609441. doi: 10.3389/fimmu.2020.609441
[22]	Tapia-Abellán A, Angosto-Bazarra D, Alarcón-Vila C, et al. Sensing low intracellular potassium by NLRP3 results in a stable open structure that promotes inflammasome activation[J]. Sci Adv, 2021, 7(38): eabf4468. doi: 10.1126/sciadv.abf4468
[23]	Fujiwara M, Matoba T, Koga JI, et al. Nanoparticle incorporating Toll-like receptor 4 inhibitor attenuates myocardial ischaemia-reperfusion injury by inhibiting monocyte-mediated inflammation in mice[J]. Cardiovasc Res, 2019, 115(7): 1244-1255. doi: 10.1093/cvr/cvz066
[24]	Song E, Jahng JW, Chong LP, et al. Lipocalin-2 induces NLRP3 inflammasome activation via HMGB1 induced TLR4 signaling in heart tissue of mice under pressure overload challenge[J]. Am J Transl Res, 2017, 9(6): 2723-2735.
[25]	Zhang L, Ai C, Bai M, et al. NLRP3 Inflammasome/Pyroptosis: A Key Driving Force in Diabetic Cardiomyopathy[J]. Inter J Mol Sci, 2022, 23(18): 10632.
[26]	Sokolova M, Sjaastad I, Louwe MC, et al. NLRP3 Inflammasome Promotes Myocardial Remodeling During Diet-Induced Obesity[J]. Front Immunol, 2019, 10: 1621.
[27]	Wei H, Bu R, Yang Q, et al. Exendin-4 protects against hyperglycemia-induced cardiomyocyte Pyroptosis via the AMPK-TXNIP Pathway[J]. J Diabetes Res, 2019, 2019: 8905917.
[28]	Ma S, Feng J, Lin X, et al. Nicotinamide riboside alleviates cardiac dysfunction and remodeling in pressure overload cardiac hypertrophy[J]. Oxid Med Cell Longev, 2021, 2021: 5546867. https://pubmed.ncbi.nlm.nih.gov/34567409/
[29]	Ren B, Feng J, Yang N, et al. Ginsenoside Rg3 attenuates angiotensin Ⅱ-induced myocardial hypertrophy through repressing NLRP3 inflammasome and oxidative stress via modulating SIRT1/NF-κB pathway[J]. Int Immunopharmacol, 2021, 98: 107841.
[30]	Pinar AA, Scott TE, Huuskes BM, et al. Targeting the NLRP3 inflammasome to treat cardiovascular fibrosis[J]. Pharmacol Ther, 2020, 209: 107511. https://pubmed.ncbi.nlm.nih.gov/32097669/
[31]	Pinar AA, Scott TE, Huuskes BM, et al. Targeting the NLRP3 inflammasome to treat cardiovascular fibrosis[J]. Pharmacol Ther, 2020, 209: 107511. https://pubmed.ncbi.nlm.nih.gov/32097669/
[32]	Bai B, Yang Y, Wang Q, et al. NLRP3 inflammasome in endothelial dysfunction[J]. Cell Death Dis, 2020, 11(9): 776. https://pubmed.ncbi.nlm.nih.gov/32948742/
[33]	Ding K, Song C, Hu H, et al. The Role of NLRP3 Inflammasome in Diabetic Cardiomyopathy and Its Therapeutic Implications[J]. Oxid Med Cell Longev, 2022, 2022: 3790721.
[34]	Wang Y, Liu X, Shi H, et al. NLRP3 inflammasome, an immune-inflammatory target in pathogenesis and treatment of cardiovascular diseases[J]. Clin Transl Med, 2020, 10(1): 91-106. https://pubmed.ncbi.nlm.nih.gov/32508013/
[35]	Bakhshi S, Shamsi S. MCC950 in the treatment of NLRP3-mediated inflammatory diseases: Latest evidence and therapeutic outcomes[J]. Int Immunopharmacol, 2022, 106: 108595. https://www.sciencedirect.com/science/article/pii/S1567576922000790
[36]	Tapia-Abellán A, Angosto-Bazarra D, Martínez-Banaclocha H, et al. Addendum: MCC950 closes the active conformation of NLRP3 to an inactive state[J]. Nat Chem Biol, 2021, 17(3): 361.
[37]	Wang M, Zhao M, Yu J, et al. MCC950, a Selective NLRP3 Inhibitor, Attenuates Adverse Cardiac Remodeling Following Heart Failure Through Improving the Cardiometabolic Dysfunction in Obese Mice[J]. Front Cardiovasc Med, 2022, 9: 727474. https://pubmed.ncbi.nlm.nih.gov/35647084/
[38]	Zhao M, Zhang J, Xu Y, et al. Selective Inhibition of NLRP3 inflammasome reverses pressure overload-induced pathological cardiac remodeling by attenuating hypertrophy, fibrosis, and inflammation[J]. Int Immunopharmacol, 2021, 99: 108046.
[39]	El-Sharkawy LY, Brough D, Freeman S. Inhibiting the NLRP3 inflammasome[J]. Molecules, 2020, 25(23): 5533. https://pubmed.ncbi.nlm.nih.gov/33255820/
[40]	Aliaga J, Bonaventura A, Mezzaroma E, et al. Preservation of Contractile Reserve and Diastolic Function by Inhibiting the NLRP3 Inflammasome with OLT1177^Ⓡ(Dapansutrile) in a Mouse Model of Severe Ischemic Cardiomyopathy Due to Non-Reperfused Anterior Wall Myocardial Infarction[J]. Moleculars, 2021 Jun 9;26(12): 3534.
[41]	Wohlford GF, Van Tassell BW, Billingsley HE, et al. Phase 1B, randomized, double-blinded, dose escalation, single-center, repeat dose safety and pharmacodynamics study of the oral NLRP3 inhibitor dapansutrile in subjects with NYHA Ⅱ-Ⅲ systolic heart failure[J]. J Cardiovasc Pharma, 2021, 77(1): 49.
[42]	Imazio M, Nidorf M. Colchicine and the heart[J]. Eur Heart J, 2021, 42(28): 2745-2760.
[43]	Li Y, Zhang Y, Lu J, et al. Anti-inflammatory mechanisms and research progress of colchicine in atherosclerotic therapy[J]. J Cell Mol Med, 2021, 25(17): 8087-8094.
[44]	Bouabdallaoui N, Tardif JC, Waters DD, et al. Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial(COLCOT)[J]. Eur Heart J, 2020, 41(42): 4092-4099.
[45]	Shen S, Duan J, Hu J, et al. Colchicine alleviates inflammation and improves diastolic dysfunction in heart failure rats with preserved ejection fraction[J]. Eur J Pharmacol, 2022, 929: 175126.
[46]	Everett BM, MacFadyen JG, Thuren T, et al. Inhibition of Interleukin-1β and Reduction in Atherothrombotic Cardiovascular Events in the CANTOS Trial[J]. J Am Coll Cardiol, 2020, 76(14): 1660-1670.
[47]	Del Buono MG, Damonte JI, Chiabrando JG, et al. Effect of IL-1 blockade with anakinra on heart failure outcomes in patients with anterior versus nonanterior ST elevation myocardial infarction[J]. J Cardiovasc Pharmacol, 2022, 79(6): 774-780.